What is the clinical evidence from this study?

Study design: Meta-Analysis. Population: Polycystic ovary syndrome (PCOS) (n=1472). Intervention: Polycystic ovary syndrome vs. Non-PCOS controls. Primary outcome: Linoleic acid levels (SMD 0.542, 95% CI 0.349, 0.736, p=<0.001).

What question did this study set out to answer?

The study aims to synthesize evidence on the fatty acid composition of blood and follicular fluid in women with polycystic ovary syndrome compared to controls.

June 14, 2026Journal of Ovarian Research0 citationsOpen Access

A systematic review and meta-analysis of fatty acid composition in polycystic ovary syndrome: perspectives from blood and follicular fluid

Q: What are the key findings of this study?

Polycystic ovary syndrome was associated with significantly elevated levels of several key fatty acids, including linoleic acid (SMD 0.542) and oleic acid (SMD 0.811), compared to non-PCOS controls.

Q: What question did this study set out to answer?

The study aims to synthesize evidence on the fatty acid composition of blood and follicular fluid in women with polycystic ovary syndrome compared to controls.

RZReza ZarezadehTabriz University of Medical Sciences AFAmir FattahiTabriz University of Medical Sciences KHKobra HamdiTabriz University of Medical Sciences

Key Result

Polycystic ovary syndrome was associated with significantly elevated levels of several key fatty acids, including linoleic acid (SMD 0.542) and oleic acid (SMD 0.811), compared to non-PCOS controls.

Key Points

The study aims to synthesize evidence on the fatty acid composition of blood and follicular fluid in women with polycystic ovary syndrome compared to controls.
Systematic search of four electronic databases until February 2025
Included twelve studies in meta-analysis
Employed random effects models for pooled standardized mean differences and assessed publication bias
Palmitoleic acid showed SMD of 0.389 (95% CI 0.121 to 0.657, p = 0.004) in the PCOS group.
Oleic acid had SMD of 0.811 (95% CI 0.107 to 1.515, p = 0.024, I 2 = 90.0%).
Linoleic acid showed significant increase with SMD of 0.542 (95% CI 0.349 to 0.736, p < 0.001).

Study Design

Type

Meta-Analysis (n=1,472)

Structured PICO

Does polycystic ovary syndrome alter the fatty acid composition in blood and follicular fluid compared to non-PCOS controls?

Population

1,472 women (842 with PCOS and 630 non-PCOS controls) from 12 observational studies assessing fatty acid composition in blood and follicular fluid.

Exposure

Polycystic ovary syndrome (PCOS) status

Comparator

Non-PCOS controls

Outcome

Fatty acid composition (levels of individual fatty acids) in blood (plasma/serum) and follicular fluidsurrogate

Women with PCOS exhibit altered fatty acid profiles, characterized by elevated levels of key mono- and n-6 polyunsaturated fatty acids in blood and follicular fluid, which may contribute to metabolic and reproductive disturbances.

Main Result

Standardized Mean Difference: 0.542 (95% CI 0.349–0.736)

p-value: p=<0.001

Limitations

Bias due to confounding, particularly neglecting the confounding effect of BMI, dietary intake, and physical activity.
Strong evidence of reporting bias arising from the incomplete provision of fatty acid data in some studies.
High statistical heterogeneity for certain fatty acids like oleic acid.
Small number of reports per outcome limited the power to detect publication bias.

Abstract

A comprehensive assessment of fatty acids (FAs) in polycystic ovary syndrome (PCOS) has yet to be carried out. The current study aimed to synthesize existing evidence on the FA composition of blood and follicular fluid (FF) in women with PCOS compared to non-PCOS controls. Four electronic databases were systematically searched until February 2025 using standard keywords. Risk of bias and evidence certainty were assessed using the ROBINS-I framework and the GRADE system, respectively. Random effects models were employed to calculate pooled standardized mean differences (SMDs) with respective 95% confidence intervals (CIs). Publication bias was inspected using funnel plots, Begg’s test, and Egger’s test. Twelve studies qualified for inclusion in the meta-analysis. Overall effect sizes for several prominent FAs, including palmitoleic acid (SMD 95% CI = 0.389 0.121, 0.657, p = 0.004, I 2 = 25.2%), oleic acid (SMD 95% CI = 0.811 0.107, 1.515, p = 0.024, I 2 = 90.0%), linoleic acid (SMD 95% CI = 0.542 0.349, 0.736, p < 0.001, I 2 = 0%), and arachidonic acid (SMD 95% CI = 0.252 0.053, 0.451, p = 0.013, I 2 = 0%), indicated an increase in the PCOS group. The direction and significance of the results partly persisted following subgroup analyses based on sample type and lipid fraction, as well as sensitivity analyses. The findings of this study suggest that FA profile may be altered in women with PCOS, primarily characterized by potential elevations in levels of key mono- and n-6 polyunsaturated FAs.

Ask AI

Helpful

Bookmark

View Full Paper